Sam H. Whiting
Bristol Royal Hospital for Children(GB)Tempest Technologies (United States)(US)
Publications by Year
Research Areas
Cancer, Hypoxia, and Metabolism, Peroxisome Proliferator-Activated Receptors, Diabetes Treatment and Management, Renal cell carcinoma treatment, Cancer Genomics and Diagnostics
Most-Cited Works
- → Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma(2016)94 cited
- → Transport and assembly of gag proteins into Moloney murine leukemia virus(1990)84 cited
- → A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors(2021)80 cited
- → Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma(2015)53 cited
- → CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study.(2019)53 cited
- → Lapatinib and Gemcitabine for Metastatic Pancreatic Cancer(2010)43 cited